# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN-TD
- Date: 2001-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Follow-up six weeks after radiotherapy for prostate cancer. **S**

## History of present illness

Mr. Mandela returns six weeks after finishing 37 fractions of radiotherapy, which he completed without a break. In the fourth week he developed urinary frequency, a weaker stream, and getting up twice a night, and radiation oncology started tamsulosin 0.4 mg in the evening; these symptoms are now improving, and he has had no burning, blood in the urine, or retention, and no dizziness on standing. In the last weeks of treatment his bowels became looser, two or three times a day with some urgency, and they are now settling to once or twice a day, with no bleeding. Asked about his bowels before treatment, he says they were regular, about once a day, as recorded at his wellness visit. His second leuprolide depot ran out about three weeks ago; hot flashes are fewer, and the tiredness he had during radiotherapy is lifting. His mood is good. He has resumed his morning walks. **S**

| Element | Detail |
|---|---|
| Radiotherapy | 74 Gy in 37 fractions, completed six weeks ago |
| Urinary | Frequency and nocturia twice, improving on tamsulosin; no blood or burning |
| Bowel | Looser stools and mild urgency, settling; no bleeding |
| Androgen deprivation | Completed; last depot ran out three weeks ago; hot flashes fading |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tiredness from radiotherapy, improving; weight stable |
| Genitourinary | Positive | Frequency and nocturia twice, improving; no burning, blood, or retention |
| Gastrointestinal | Positive | Stools once or twice a day, softer than before, with mild urgency; no bleeding |
| Endocrine | Positive | Occasional hot flashes, fewer than before |
| Neurological | Negative | No dizziness on standing |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily **S**
- Tamsulosin 0.4 mg oral capsule, one capsule by mouth once daily after the evening meal, for urinary frequency during radiotherapy **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/74 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 81.4 kg; BMI 24.3 kg/m². All vital signs are synthetic.

PSA: 0.4 ng/mL; Total testosterone: 38 ng/dL (low); IPSS total (0 to 35): 12; PHQ-2: 0. All results are synthetic.

## Change since baseline

- PSA: 6.4 ng/mL (high) at baseline, 0.4 ng/mL at this visit **S**
- Total testosterone: 412 ng/dL at baseline, 38 ng/dL (low) at this visit **S**
- IPSS total (0 to 35): 7 at baseline, 12 at this visit **S**

## Immunizations given today

- High-dose influenza vaccine, this season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 128/74 mm Hg seated; no ankle swelling |
| Abdomen | Soft and non-tender; bladder not palpable |
| Skin | Mild hyperpigmentation over the treated area only; skin intact |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Prostate cancer, unfavorable intermediate risk, after radiotherapy with androgen deprivation** (C61). PSA 0.4 ng/mL six weeks after radiotherapy and three weeks after the end of androgen deprivation. The PSA nadir is usually reached over one to two years; a small temporary rise (a bounce) can occur and is not recurrence. Recurrence after radiotherapy is defined as a PSA rise of 2 ng/mL above the nadir (Phoenix). **S**
   - PSA every six months for five years, then yearly.
   - Written survivorship care plan given today, with the surveillance schedule and symptoms to report.
2. **After external beam radiotherapy** (Z92.3). Grade 1 urinary and bowel effects of radiotherapy, both improving. IPSS 12, up from 7 before treatment. **S**
   - Continue tamsulosin 0.4 mg in the evening; review at the next visit, with a view to stopping it once symptoms settle.
   - Report blood in the urine or rectal bleeding at any time, which would need urology or gastroenterology assessment.
3. **Androgen deprivation therapy: completed** (Z79.899). Testosterone 38 ng/dL, still low; it recovers slowly over months at his age, and hot flashes, fatigue, and weight should improve as it does. **S**
   - Testosterone with the next PSA.
   - Lipid panel and A1c at one year; DXA again in one to two years.
   - Continue cholecalciferol 1000 units daily and resistance exercise.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA after radiotherapy | Every 6 to 12 months for 5 years, then yearly | Completed today | 0.4 ng/mL, first value after radiotherapy; next in six months |
| Laboratory | Testosterone recovery | With PSA after androgen deprivation ends | Completed today | 38 ng/dL, not yet recovered |
| Laboratory | Hemoglobin A1c or fasting glucose, and lipid panel | Yearly after androgen deprivation | Due | Due in four months, one year after baseline |
| Imaging | Bone density (DXA) | Every 1 to 2 years after androgen deprivation | Up to date | Baseline six months ago; next in one to two years |
| Examination | Digital rectal examination | Yearly after curative treatment | Due | Not useful this soon after radiotherapy; due in one year |
| Examination | Blood pressure and cardiovascular assessment | Every visit while on androgen deprivation and after | Completed today | 128/74 mm Hg seated; no dizziness on standing on tamsulosin |
| Survey | Urinary symptoms (IPSS) | Every follow-up visit, particularly the first two years | Completed today | IPSS 12, up from 7 before treatment; improving on tamsulosin |
| Survey | Bowel function after radiotherapy | Every visit after radiotherapy | Completed today | Softer stools once or twice a day with mild urgency, settling; no bleeding |
| Survey | Bowel baseline missed before radiotherapy | Baseline before radiotherapy | Deferred | Not asked at the visit before radiotherapy, a deviation from the protocol. The wellness visit five weeks before that had recorded regular, formed stools once a day, and he confirms this today, so a baseline was available and no harm resulted. The bowel question is now on the pre-radiotherapy checklist |
| Survey | Sexual function | Periodically after treatment | Completed today | Reviewed; expected recovery after androgen deprivation explained; no treatment requested |
| Medication safety | Hot flashes and fatigue | Every visit until androgen deprivation effects resolve | Completed today | Fewer hot flashes; fatigue from radiotherapy improving |
| Survey | Distress and depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 0 |
| Survey | Cognition | Periodically after androgen deprivation | Up to date | Mini-Cog 5 of 5 at the wellness visit; no change reported |
| Self-management | Survivorship care plan and lifestyle | After treatment; lifestyle every visit | Completed today | Written plan given; walking resumed; no tobacco |

## Goal progress

- Reach an informed, shared decision on treatment after hearing every reasonable option, including observation. Outcome by 2001-04-14: Radiotherapy with six months of androgen deprivation chosen at the radiation oncology consultation. **S**
- Complete six months of androgen deprivation and the course of radiotherapy with side effects managed. Outcome by 2001-10-27: Two leuprolide depots and 37 fractions completed; testosterone castrate on treatment; mild hot flashes and urinary frequency, managed. **S**
- Protect bone health on androgen deprivation: baseline DXA, vitamin D of 30 ng/mL or more, dietary calcium, and weight-bearing exercise. Outcome by 2001-07-14: Femoral neck T-score -1.4; vitamin D 34 ng/mL on supplementation; walking daily. **S**
- PSA falling after radiotherapy, with a written surveillance plan. Outcome by 2001-10-27: PSA 0.4 ng/mL six weeks after radiotherapy; PSA every six months planned. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022), American Urological Association and American Society for Radiation Oncology
- Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014), American Cancer Society
- CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026), Aether Forge

## Follow-up

- Primary care in three months to review tamsulosin and urinary and bowel symptoms. PSA and testosterone in six months. Radiation oncology review in six weeks, three months after treatment. Influenza vaccine given today. **S**

